Advertisement

Mammakarzinom in Schwangerschaft und Stillzeit

  • S. Adler-Ganal
Part of the Onkologie Aktuell book series (ONKAKTUELL)

Zusammenfassung

Zwar sind maligne Erkrankungen die Haupttodesursache bei Frauen im gebärfähigen Alter (Silverberg u. Lubera 1986), das Auftreten in der Schwangerschaft ist jedoch relativ selten. Schätzungsweise tritt etwa eine Tumorerkrankung auf 1000 Schwangerschaften auf. Die häufigsten malignen Erkrankungen während der Schwangerschaft sind Tumore aus dem gynäkologischen Bereich. In der Inzidenz führend sind das Zervix- und das Mammakarzinom (Haas 1984; Winkelmann u. Schneider 1991) (Tabelle 20.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ataya K, Moghissi K (1989) Chemotherapy-induced premature ovarian failure: mechanism and prevention. Steroids 54: 607–626PubMedCrossRefGoogle Scholar
  2. Ataya K, Ramahi-Ataya A (1993) Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 7: 229–235PubMedCrossRefGoogle Scholar
  3. Aviles A, Diaz Maqueo JC, Talavera A, Guzman R, Garcia EL (1992) Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 36: 243–248CrossRefGoogle Scholar
  4. Awidi AS, Tarawneh MS, Shubair KS, Issa AA, Dajani YF (1983) Acute leukemia in pregnancy. Report of five cases treated with a combination which included a low dose of adriamycin. Europ J Cancer Clin Oncol 19: 881PubMedCrossRefGoogle Scholar
  5. Baltzer, Konecny, Untch (1996) Mammakarzinom und Schwangerschaft. Mammakarzinom-Manual, Tumorzentrum München, S 103–106Google Scholar
  6. Barnavon Y, Wallack MK (1990) Management of the pregnant patient with carcinoma of the breast. Surgery, Gynecol Obstetr 171:347–351Google Scholar
  7. Barker GH (1983) Cytotoxic drugs in pregnancy. In: Lewis P, Wright PSG (eds) Clinical pharmacology in obstetrics. Bristol, pp 144–155Google Scholar
  8. Barnicle MM (1992) Chemotherapy and pregnancy. Sem Oncol Nurs 8/2:124–132CrossRefGoogle Scholar
  9. Blatt J et al. (1980) Pregnancy outcome following cancer chemotherapy. Am J Med 69: 828–832PubMedCrossRefGoogle Scholar
  10. Berkowitz RL, Coustan DR, Mochizuki TK (1986) Handbook for prescibing medications during pregnancy, 2nd edn. Little, Brown, BostonGoogle Scholar
  11. Brincker H et al. (1989) Castration induced by cytotoxic chemotherapy. Letter. J Clin Oncol 7:679–680Google Scholar
  12. Buscema ZA, Stern JL, Johnson TRB (1988) Antineoplastic drugs and pregnancy. In: Niebly JR (ed) Drug use in pregnancy, 2nd edn. Niebly, Lea &; Febiger, pp 89–108Google Scholar
  13. Chang YT, Loong CC, Wang HC, Jwo SC, Lui WY (1994) Breast cancer and pregnancy. Chin Med J 54: 223–229Google Scholar
  14. Chaube S, Murphy ML (1965) Teratogenic effects of cytosine arabinoside (CA) in the rat fetus. Proc Am Assoc Cancer Res 6:11Google Scholar
  15. Chaube S et al. (1967) Teratogenic effects of cyclophosphamide in the rat. Cancer Chemother Rep 51:363–376Google Scholar
  16. Chaube S, Murphy ML (1968) The teratogenic effects of the recent drugs active in cancer chemotherapy. In: Woollam DHM (ed) Advances in teratology, vol 3. Academic Press, New York, pp 204–205Google Scholar
  17. Coates A (1970) Cyclophosphamide in pregnancy. Aust NZ J Obstet Gynecol 10:33–34CrossRefGoogle Scholar
  18. Committee on Drugs, American Academy of Pediatrics (1989) The transfer of drugs and other chemicals into human breast milk. Pediatrics 84: 924–936Google Scholar
  19. Dagg CP (1960) Sensitive stages for the production of developmental abnormalities in mice with 5-fluorouracil. Am J Anat 106:89–96PubMedCrossRefGoogle Scholar
  20. Dara P et al. (1981) Successful pregnancy during therapy for acute leukemia. Cancer 47: 845–846PubMedCrossRefGoogle Scholar
  21. Darab DJ, Minkoff R, Sciote J et al. (1987) Pathogenesis of median facial clefts in mice treated with methotrexate. Teratology 36: 77–88PubMedCrossRefGoogle Scholar
  22. Diniz EMA, Corradini HB, Ramos JL et al. (1978) The effects of methotrexat on the developing fetus. Rev Hosp Clin Fac Med, Univ Sao Paulo 33: 286–290Google Scholar
  23. Doll DC, Ringenberg QS, Yarbro JW (1988) Management of cancer during pregnancy. Arch Intern Med 148: 2058–2074PubMedCrossRefGoogle Scholar
  24. Doll DC, Ringenberg QS, Yarbro JW (1989) Antineoplastic agents and pregnancy. Semin Oncol 16:337–346PubMedGoogle Scholar
  25. Durodola JI (1979) Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Natl Med Assoc 71:165PubMedGoogle Scholar
  26. Egan PC, Costanza ME, Dodion P, Egorion MJ, Bachur NR (1985) Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep 69:1387–1389PubMedGoogle Scholar
  27. Elledge RM, Ciocca DR, Langone G, McGuire WL (1992) Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71: 2499–2509CrossRefGoogle Scholar
  28. Fantel AG et al. (1985) The embryotoxicity of adramycin in rat embryos in vitro. Toxicol Appl Pharmacol 80:155–165PubMedCrossRefGoogle Scholar
  29. Fritz H, Hess R (1971) Effects of cyclophosphamide on embryonic development in the rabbit. Agents Actions 2: 83–86PubMedCrossRefGoogle Scholar
  30. Gallenberg MM, Loprinzi CL (1989) Breast cancer and pregnancy. Semin Oncol 16:369–373PubMedGoogle Scholar
  31. Garcia V, San Miguel J, Borrasca AL (1981) Doxorubicin in the first trimester of pregnancy. Ann Intern Med 94:547PubMedCrossRefGoogle Scholar
  32. Gerlinger P, Clavert J (1965) Ano alies observees chez des lapins issus de meres traitees au cyclophosphamide. C R Soc Biol 159:1462–1466Google Scholar
  33. Gililland J, Weinstein L (1983) The effects of cancer chemotherapeutic agents on the developing fetus. Obstet Gynecol Surv 38: 6–13PubMedGoogle Scholar
  34. Gleicher N, Scigel I (1981) Common denominators of pregnancy and malignancy. Prog Clin Biol Res 70:339–341PubMedGoogle Scholar
  35. Haas JF (1984) Pregnancy in association with a newly diagnosed cancer. A population-based epidemiologic assessment. Int J Cancer 34: 229PubMedCrossRefGoogle Scholar
  36. Hackenberger I, Kreybig T (1965) Vergleichende teratologische Untersuchungen bei der Maus und der Ratte. Arzneim Forsch 15:1456–1460Google Scholar
  37. Hansmann I (1974) Chromosome aberrations in metaphase II-oocytes stage sensitivity in the mouse oogenesis to amethopterin and cyclophosphamide. Mutat Res 22:175–191PubMedCrossRefGoogle Scholar
  38. Hasan C, Fleischhack G, Bode U (1995) Fetale Risiken bei zytotoxischer Malignombehandlung in der Schwangerschaft. Deutscher Krebskongress 20.10.01, Abstractband 22, S184Google Scholar
  39. Hassenstein E, Riedel H (1978) Zur Teratogenität von Adriamycin ein Fallbericht. Geburtshilfe Frauenheilkde 38:131–133Google Scholar
  40. Hendrickx AG, Peterson PE, Rowland JR, Tarantal AF (1991) Early embryonic sensitivity to cyclophosphamid in long-tailed monkeys (Macaca fascicularis). Teratology 43:445Google Scholar
  41. Hoeffken W, Lanyi M (1977) Mammography. Saunders, PhiladelphiaGoogle Scholar
  42. Isaacs JH (1995) Cancer of the breast in pregnancy. Surg Clin North America 75: 47–55Google Scholar
  43. Ishida T, Yokoe T, Kasumi F et al. (1992) Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn — J — Cancer — Res 83(11): 1143–1149PubMedCrossRefGoogle Scholar
  44. Jensen MK, Nyfors A (1979) Cytogenetic effect of methotrexate on human cells in vivo. Comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by micronucleus test. Mutat Res 64:339–343PubMedCrossRefGoogle Scholar
  45. Johns DG, Rutherford LD, Leighton PC, Vagel CI (1972) Secretion of methotrexate into human milk. Am J Obstet Gynecol 112:978–980PubMedGoogle Scholar
  46. Jordan RL, Wilson JG, Schumacher HJ (1977) Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 15:73–80PubMedCrossRefGoogle Scholar
  47. Karp GI, von Oyen P, Valone F et al. (1983) Doxorubicin in pregnancy: possible transplacental passage. Cancer Treatm Rep 67:773–777Google Scholar
  48. Kirshon B et al. (1988) Teratogenic effects of first trimester cyclophosphamide therapy. Obstet Gynecol 72:462PubMedGoogle Scholar
  49. Khera KS (1976) Teratogenicity studies with methotrexate, aminopterin, and acetylsalicyclic acid in domestic cats. Teratology 14:21–28PubMedCrossRefGoogle Scholar
  50. Kopelman JN, Miyazawa K (1990) Inadvertent 5-fluorouracil treatment in early pregnancy: a report of three cases. Reprod Toxicol 4:233–235PubMedCrossRefGoogle Scholar
  51. Knörr K, Rauskolb R (1992) Pharmakogene Fruchtschäden. Geburtshilfe, Bd I, Sonderdruck. Thieme, Stuttgart, S 89–96Google Scholar
  52. Kreuser ED, Klingmüller D, Thiel E (1992) Diagnostik und Prognose gonadaler Toxizität nach Chemotherapie und Bestrahlung. Dtsch Med Wochenschr 117:1810–1817PubMedCrossRefGoogle Scholar
  53. Khurshid M, Saleem M (1978) Acute leukemia in pregnancy. Lancet II: 534–535CrossRefGoogle Scholar
  54. Leinmüller R (1996) Fertilität nach Chemotherapie. Schädigung der Ovarien kann minimiert werden. Deutsches Ärzteblatt 93/40: B-1989Google Scholar
  55. Lochry E, Kai S, Kohmura H, Kadota T, Takahashi N (1995) Reproductive safety evaluation of paclitaxel in rats. Toxicologist 15: in pressGoogle Scholar
  56. Lowenthal RM et al. (1982) Normal infant after combination chemotherapy including teniposide for Burkitts’ lymphoma in pregnancy. Med Pediatr Oncol 10:165–169PubMedCrossRefGoogle Scholar
  57. Maher JF, Schreiner GE (1970) Treatment of lupus nephritis with azathioprine. Arch Intern Med 125:293–298PubMedCrossRefGoogle Scholar
  58. Marazzini F, Macchi L (1966) Two normal pregnancies in patients receiving Cytoxan for Hodgkin’s disease. Ann Obstet Gynecol 88: 825–834Google Scholar
  59. Marchant DJ (1994) Breast cancer in pregnancy. Clin Obst Gyn 37:993–997CrossRefGoogle Scholar
  60. Max MH, Klamer TW (1983a) Pregnancy and breast cancer. So Med J 25:241–242Google Scholar
  61. Max MH, Klamer TW (1983b) Pregnancy and breast cancer. So Med J 76: 1008–1090CrossRefGoogle Scholar
  62. Menutti MT, Shepard TH, Mellman WJ (1975) Fetal renal malformation following continuous treatment with adriamycin, bleomycin, vinblastine and imidazole carboxa-mide (ABVD) after failure of MOPP therapy. Cancer 41: 2107–2111Google Scholar
  63. Milunsky A, Graef JW, Gaynor MF (1968) Methotrexat-induced congenital malformations. J Pediatr 72:790–795PubMedCrossRefGoogle Scholar
  64. Mondello C, Giorgi R, Nuzzo F (1984) Chromosomal effects of methotrexate on cultured human lymphocytes. Mutat Res 139:67–70PubMedCrossRefGoogle Scholar
  65. Mulvihill JJ, McKeen EA, Rosner F et al. (1987a) Pregnancy outcome in cancer patients. Cancer 60:1143–1150PubMedCrossRefGoogle Scholar
  66. Murray CL, Reichert JA, Anderson J et al. (1984) Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA 252: 2607–2608PubMedCrossRefGoogle Scholar
  67. Mutchinick O, Aizpuru E, Grether P (1992) The human teratogenic effect of cyclophosphamide. Teratology 45:329Google Scholar
  68. Newcomb M, Balducci L, Thigpen JT, Morrison FS (1978) Acute leukemia in pregnancy: sucessful delivery after cytarabine and doxorubicin. JAMA 239: 2691–2692PubMedCrossRefGoogle Scholar
  69. Nicholson HO (1968) Cytotoxic drugs in pregnancy. J Obstet Gynecol 75:307–312Google Scholar
  70. Odom LD, Plouffe JR, Butler WJ (1990) 5-fluoruracil exposure during the period of conception: A report on two cases. Am J Obstet Gynecol 163:76–77PubMedGoogle Scholar
  71. Oguro T et al. (1973) Toxicological studies on adriamycin-HCL. 4. Teratology study. Yakubutsu Ryoho 6:1152–1164Google Scholar
  72. Ono C, Iwama A, Fujiwara Y, Kitsuya A, Nakamura T (1992) Teratology study of idarubicin hydrochloride in rats in intravenous injection. Shinyaku to Rinsho 41: 2958–2987Google Scholar
  73. Petrek JA, Dukoff R, Rogatko A (1991) Prognosis of pregnancyassociated breast cancer. Cancer 67: 869–872PubMedCrossRefGoogle Scholar
  74. Petrek JA (1991) Pregnancy-associated breast cancer. Sem Surg Oncol 7:306–310CrossRefGoogle Scholar
  75. Pizzuto et al. (1980) Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 64: 679–683PubMedGoogle Scholar
  76. Powell HR, Ekert H (1971) Methotrexat-induced malformations. Med J Aust 2:1076–1077PubMedGoogle Scholar
  77. Reynoso EE, Shepard FA, Messner HA et al. (1987) Acute leukemia during pregnancy: The Toronto Leukemia Studie group experience with long-term follow-up of children exposed in utero to chemotherapeutic agent. J Clin Oncol 5:1098–1106PubMedGoogle Scholar
  78. Rister M, Müller AM, Gladtke E (1983) Kinder ehemaliger krebskranker Patienten. Dtsch Med Wochenschr 108: 1137–1140PubMedCrossRefGoogle Scholar
  79. Roboz J, Gleicher N, Wu K et al. (1979) Does doxorubicin cross the placenta? Lancet II, Dec 22/29:1382–1383Google Scholar
  80. Rosenshein NB et al. (1979) Pregnancy following chemotherapy for an ovarian immature embryonal teratoma. Gynecol Oncol 24:268–270Google Scholar
  81. Rustin GJS, Booth M, Dent J et al. (1984) Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumors. Br Med J 288:103–106CrossRefGoogle Scholar
  82. Sanders JE, Bruckner CD et al. (1983) Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 36: 252PubMedCrossRefGoogle Scholar
  83. Sanders JE, Bruckner CD, Amos D et al. (1988) Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 6: 813PubMedGoogle Scholar
  84. Schoultz E, Johannson H, Wilking N, Rutqvist LE (1995) Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13: 430–434Google Scholar
  85. Scialli AR, DeSesso JM, Rahman A, Husain SR, Goeringer GC (1995) Dose-response comparison of free and liposome-encapsulated taxol. Teratology 51:169Google Scholar
  86. Scialli AR, Waterhouse TB, DeSesso JM, Rahman A, Goeringer GC (1997) Protective effect of Liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology 56:305–310PubMedCrossRefGoogle Scholar
  87. Scialli AR, DeSesso JM, Goeringer GC (1994) Taxol toxicity in the developing chick. Teratology 45: 478Google Scholar
  88. Scialli AR, DeSesso JM, Goeringer GC (1992) Taxol and embryonic development in the chick. Teratogen Carcinog Mutagen 14: 23–30CrossRefGoogle Scholar
  89. Silverberg E, Lubera J (1986) Cancer statistics. CA 36:9PubMedGoogle Scholar
  90. Sinkovics JG, Shullenberger CC (1969) Pregnancy and systemic malignant disease. Cancer Chemother Rep 53:94Google Scholar
  91. Skalko RG, Gold MP (1974) Teratogenicity of methotrexate in mice. Teratology 9:159–164PubMedCrossRefGoogle Scholar
  92. Sosa Munoz JL, Perez Santana MT, Sosa Sanchez R et al. (1983) Acute leukemia and pregnancy. Rev Invest Clin (Mex) 35:55–58Google Scholar
  93. Stadler HE, Knowles J (1971) Fuoruracil in pregnancy: effect on the neonate. JAMA 217: 214–215PubMedCrossRefGoogle Scholar
  94. Stephens JD, Golbus MS, Miller TR, Wilber RR et al. (1980) Multiple congenital anomalies in a fetus exposed to 5-fluoruracil during the first trimester. Am J Obstet Gynecol 137:747–749PubMedGoogle Scholar
  95. Sweet DL, Kinzie J (1976) Consequences of radiotherapy and antineoplastic therapy to the fetus. J Reprod Med 17:241–246PubMedGoogle Scholar
  96. Symington GR et al. (1977) Cancer and teratogenesis. Infrequent occurrence after medical use of immuno-suppressive drugs. Aust N Z J Med 7: 376–378Google Scholar
  97. Thomas PR, Biochem D, Peckham MJ (1976) The investigation and management of Hodgkin’s disease in the pregnant patient. Cancer 38:1443–1451PubMedCrossRefGoogle Scholar
  98. Thompson DJ (1974) Reproduction and teratology studies with oncolytic agents in the rat and the rabbit. I. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Toxicol Appl Pharmacol 30: 422–439PubMedCrossRefGoogle Scholar
  99. Tobias JS, Bloom HJG (1980) Doxorubicin in pregnancy. Lancet, Apr 5: 776CrossRefGoogle Scholar
  100. Toledo TM et al. (1971) Fetal effects during cyclophosphamide and irridiation therapy. Am Intern Med 74: 87–91CrossRefGoogle Scholar
  101. Turchi JJ, Villasis C (1988) Anthracyclines in the treatment of malignancy in pregnancy. Cancer 61: 435–440PubMedCrossRefGoogle Scholar
  102. van Thiel DH, Ross GT, Lipsett MB (1970) Pregnancies after chemotherapy of throphoblastic neoplasma. Science 169: 1326–1327PubMedCrossRefGoogle Scholar
  103. Voorhees JJ, Janzen MK, Harrell ER, Chakrabarti SG (1969) Cytogenetic evaluation of methotrexate-treated psoriatic patients. Arch Derm 100:269–274PubMedCrossRefGoogle Scholar
  104. Wallack MK, Wolf JA, Bedwenek J et al. (1983) Gestational carcinoma of the female breast. Curr Probl Cancer 7:1–58PubMedCrossRefGoogle Scholar
  105. Warkany J (1978) Aminopterin und Methotrexat: folic acid deficiency. Teratology 17:353–358PubMedCrossRefGoogle Scholar
  106. Wiernick PH, Duncan JH (1971) Cyclophosphamide in human milk. Lancet 1:912CrossRefGoogle Scholar
  107. Wilk AL et al. (1978) Induction of malformations in the rhesus monkey with cyclophosphamide. Teratology 17: 24aGoogle Scholar
  108. Wilson JG, Scott WJ, Ritter EJ, Fradkin R (1979) Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology 19:71–80PubMedCrossRefGoogle Scholar
  109. Wilson JG (1971a) Use of rhesus monkeys in teratological studies. Fed Proc 30:104–109PubMedGoogle Scholar
  110. Winkelmann M, Schneider W (1991) Tumortherapie in der Schwangerschaft. Dtsch Med Wochenschr 116:670–673PubMedGoogle Scholar
  111. Yamashita H, Tateda C, Yamamae H, Kuzuoka K, Ishitobi H, Nakamura T (1992) Fertility study of idarubicin hydrochloride in rats by intavenous injection. Shinyaku to Rinsho 41: 2948–2957Google Scholar
  112. Zemlickis D, Lishner M, Ehrlich R, Koren G (1992) Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratogen Carcinog Mutagen 13:139–143CrossRefGoogle Scholar
  113. Zirvi KA et al. (1985) Embryotoxic effects of doxorubucin and N-trifluroacetyladriamycin-14-valerate (AD-32). Teratology 31: 247–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • S. Adler-Ganal

There are no affiliations available

Personalised recommendations